PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers.  With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing and formalizing its PLA practice to offer the biopharmaceutical industry unparalleled expert advice for planning and negotiating PLAs.  PDCI will be announcing more details on its PLA services in the coming days.  In the interim,  please do not hesitate to contact Neil Palmer, or Kaitlyn Proulx.